http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110964078-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-008 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J63-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 |
| filingDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110964078-B |
| titleOfInvention | Hederagenin compound H-X with anti-lung cancer effect and preparation method and application thereof |
| abstract | The invention provides an hederagenin compound H-X with an anti-tumor effect, a preparation method and application thereof, and the structural general formula 1 is as follows. Most of the derivatives have obvious inhibition effect on tumor cells A549, MCF-7 and HepG2, wherein the compound hederagenin-2, 6-dimethyl pyrazine (H-08) shows better selectivity between tumor and normal, especially on lung cancer A549 cells. The inhibition effect on A549 cells is similar to that of positive drug cisplatin (IC 50) on IC50 of A549 cells, MCF-7 cells, HepG2 cells, MDCK cells and H9c2 cells, wherein the IC50 of the A549 cells, the MCF-7 cells, the HepG2 cells, the MDCK cells and the H9c2 cells are respectively 3.45 +/-0.59 mu M, 8.73 +/-1.49 mu M, 8.71 +/-0.38 mu M, 14.11 +/-0.04 mu M and 16.69 +/-0.12 mu M 50 3.85 ± 0.63 μ M), but the toxicity to MDCK and H9c2 was significantly lower than that of cisplatin. |
| priorityDate | 2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.